93 related articles for article (PubMed ID: 28394971)
21. Pareto's law and sulfonylureas.
Peiris AN; Micklewright M; Gangadharan V
South Med J; 2007 Nov; 100(11):1072-3. PubMed ID: 17984734
[No Abstract] [Full Text] [Related]
22. Sulfonylureas improve insulin binding and insulin action in non-insulin-dependent diabetes mellitus.
Beck-Nielsen H; Hjøllund E; Pedersen O; Richelsen B; Sørensen NS
Diabetes Care; 1984; 7 Suppl 1():100-5. PubMed ID: 6428842
[TBL] [Abstract][Full Text] [Related]
23. Late complications of diabetes mellitus: risk factors in patients on sulfonylureas for more than 10 years.
Hoshi M; Fujita S
Jpn J Med; 1991; 30(6):616-7. PubMed ID: 1798228
[No Abstract] [Full Text] [Related]
24. [Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Pro].
Nauck MA
Dtsch Med Wochenschr; 2011 Mar; 136(11):546. PubMed ID: 21351041
[No Abstract] [Full Text] [Related]
25. Sulfonylurea use is associated with larger infarct size in patients with diabetes and ST-elevation myocardial infarction.
Abdelmoneim AS; Welsh RC; Eurich DT; Simpson SH
Int J Cardiol; 2016 Jan; 202():126-30. PubMed ID: 26386939
[TBL] [Abstract][Full Text] [Related]
26. Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients.
Harmsze AM; Van Werkum JW; Moral F; Ten Berg JN; Hackeng CM; Klungel OH; De Boer A; Deneer VH
Platelets; 2011; 22(2):98-102. PubMed ID: 21142408
[TBL] [Abstract][Full Text] [Related]
27. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
[TBL] [Abstract][Full Text] [Related]
29. Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): good for sulfonylureas?
Al-Ozairi E; Sibal L; Home P
Diabetes Care; 2007 Jun; 30(6):1677-80. PubMed ID: 17351288
[No Abstract] [Full Text] [Related]
30. Exploring the role of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus.
Graham JP; Stam D
Pharm Pract Manag Q; 1997 Oct; 17(3):1-9. PubMed ID: 10173306
[TBL] [Abstract][Full Text] [Related]
31. Time to be cautious about prescribing sulfonylureas?
Dwyer M
Br J Gen Pract; 2015 Feb; 65(631):93-4. PubMed ID: 25624301
[No Abstract] [Full Text] [Related]
32. Sulfonylureas and the risk of myocardial infarction.
Thisted H; Johnsen SP; Rungby J
Metabolism; 2006 May; 55(5 Suppl 1):S16-9. PubMed ID: 16631805
[TBL] [Abstract][Full Text] [Related]
33. [Identification, function mechanisms and regulation of potassium channels sensitive to ATP which are targets of sulfonylureas used in the treatment of type II diabetes mellitus].
Fosset M; De Weille J; Schmid-Antomarchi H; Bernardi H; Lazdunski M
Journ Annu Diabetol Hotel Dieu; 1989; ():7-11. PubMed ID: 2503655
[No Abstract] [Full Text] [Related]
34. Beyond sulfonylureas: new oral medications in the treatment of NIDDM (type II DM).
Capriotti T
Medsurg Nurs; 1997 Jun; 6(3):166-9. PubMed ID: 9238992
[No Abstract] [Full Text] [Related]
35. [Sulfonylureas and glinides].
Kudo K; Hirose T
Nihon Rinsho; 2011 Jan; 69 Suppl 1():645-53. PubMed ID: 21766676
[No Abstract] [Full Text] [Related]
36. Oral sulfonylureas and CV mortality.
Aronow WS
Geriatrics; 2004 Sep; 59(9):45-6, 49. PubMed ID: 15461238
[No Abstract] [Full Text] [Related]
37. The second generation sulfonylureas: glipizide and glyburide.
Baker DE; Campbell RK
Diabetes Educ; 1985; 11(3):29-36. PubMed ID: 3935402
[No Abstract] [Full Text] [Related]
38. Is There Enhanced Risk of Cerebral Ischemic Stroke by Sulfonylureas in Type 2 Diabetes?
Parkinson FE; Hatch GM
Diabetes; 2016 Sep; 65(9):2479-81. PubMed ID: 27555575
[No Abstract] [Full Text] [Related]
39. Risk factors associated with treatment discontinuation and down-titration in type 2 diabetes patients treated with sulfonylureas.
Iglay K; Qiu Y; Steve Fan CP; Li Z; Tang J; Laires P
Curr Med Res Opin; 2016 Sep; 32(9):1567-75. PubMed ID: 27175740
[TBL] [Abstract][Full Text] [Related]
40. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider.
Bowker SL; Majumdar SR; Veugelers P; Johnson JA
Diabetes Care; 2006 Aug; 29(8):1990-1. PubMed ID: 16873829
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
